Abstract. The elevated expression of urokinase-type plasminogen activator receptor (uPAR) is associated with the poor prognosis of pancreatic cancer patients. Thus, uPAR is a promising candidate as a molecular target for the non-invasive imaging of pancreatic cancer. The present study aimed to develop a technetium-99m ( 99m Tc)-labeled uPAR-binding peptide for non-invasive single-photon emission computed tomography (SPECT) assessment of uPAR expression in pancreatic cancer xenograft models. A linear high-affinity uPAR peptide antagonist, Hynic-PEG-AE105, was labeled with 99m Tc. Human uPAR-positive pancreatic cancer BxPC-3 cells were inoculated into nude mice. SPECT was performed in the pancreatic cancer xenograft mice models. The results showed that the rate of the 99m Tc labeling of Hynic-PEG-AE105 was 97.72±1.73%. The tumor uptake of 99m Tc-Hynic-PEG-AE105 was higher than the control inactive peptide 99m Tc-Hynic-PEG-AE105mut at 4 h (3.37±0.11 vs. 1.36±0.18; P<0.001) and 6 h (3.64±0.25 vs. 1.28±0.20; P<0.001) (n=10). Moreover, a significant correlation was observed between the tumor uptake of 99m Tc-Hynic-PEG-AE105 and uPAR expression (r= 0.791, P= 0.006). In conclusion, in the present study, a peptide-based SPECT tracer, 99m Tc-Hynic-PEG-AE105, with a high purity and specific radioactivity was synthesized. Tc-Hynic-PEG-AE105 is a promising agent for the non-invasive determination of uPAR expression in pancreatic cancer.
Introduction
Pancreatic cancer is the 13th most common type of cancer, and the 8th leading cause of cancer-related mortality, accounting for 6.9% of all cancer-related mortalities, worldwide (1) . The initial symptoms of pancreatic cancer are often nonspecific, such as nausea, fatigue, jaundice, weight loss, light-colored stools, dark urine and pain in the back or stomach area (2) . Pancreatic cancer may be treated with surgery, radiotherapy or chemotherapy (3) . Chemotherapy and radiation therapy are important adjuvant or neoadjuvant therapies, particularly for patients with unresectable disease (4) . Pancreatic cancer has an extremely poor prognosis; the median survival time for all patients is 4-6 months, and the overall five-year survival rate is 7.2% (1) . Emerging evidence suggests that the serine-protease urokinase-type plasminogen activator (uPA) and its receptor (uPAR) are significant in pancreatic cancer invasion and metastasis (5) (6) (7) . Overexpression of uPAR in pancreatic cancer has been determined to be a strong and independent predictor of short overall survival (6) . uPAR is recognized as a novel marker of cancer invasion and metastasis, and is a promising candidate as a molecular target for cancer therapy (8, 9) . The ability to visualize and quantify uPAR expression non-invasively in vivo is required for the potential clinical application of anticancer therapy based on the uPA/uPAR system (10, 11) .
Therefore, in the present study, a high-affinity 9-mer peptide antagonist of uPA-uPAR (AE105) was selected to develop a technetium-99m ( 99m Tc)-labeled tracer for non-invasive single-photon emission computed tomography (SPECT) assessment of uPAR expression in pancreatic cancer.
99m Tc-Hynic-PEG-AE105 was prepared, together with a non-binding version ( 99m Tc-Hynic-PEG-AE105mut) as a control, and the quantitative association between tracer uptake and uPAR expression was investigated in pancreatic tumor tissues. -(~10 mCi) in 80 µl S n CL 2 •H 2 O (1 mg/ml) were diluted in 160 µl Hynic-PEG-AE105 (1 mg/ml), followed by incubation at room temperature for 10 min.
Materials and methods

Reagents
Purification of
99m Tc-labeled peptides. Tc-labeled peptide was subsequently purified using Sep-Pak Light C18 cartridges (Waters Corporation, Milford, MA, USA), as described previously (13) , and diluted with 8 volumes of water for injection. To determine the specific radioactivity of the labeled peptides, radioactivity was measured by a dose calibrator (CRC-25R; Capintec Inc., Ramsey, NJ, USA) following the manufacturer's instructions.
Pancreatic cancer xenografts in nude mice. The animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Dalian Medical University (Dalian, Liaoning, China). Sodium pentobarbital anesthesia was used to minimize animal suffering. Male nude mice (4-5 weeks old) were obtained from Dalian Medical University Animal Center, and kept under pathogen-free conditions in accordance with the guidelines of the IACUC of Dalian Medical University. For the xenograft tumor growth assay, BxPC-3 cells were obtained from the Chinese Academy of Sciences (Shanghai, China) and the cultured cells (1x10 6 cells) were injected subcutaneously into the right flank of the mice, which were anesthetized with 2% sodium pentobarbital (dose, 45 mg/kg weight). At 2 weeks post-inoculation, the tumor size was measured every 3-4 days until the tumors grew to a diameter of 10 mm or until the tumor burden exceeded 10% of their body weight, at which time the mice were enrolled in SPECT studies.
Biodistribution studies. In brief, the nude mice bearing BxPC-3 xenografts were injected into the tail vein with 18. Tc-Hynic-PEG-AE105mut. The mice were euthanized at 0.5, 1, 2, 4 or 8 h post-injection. Blood, tumor and major organs were collected (wet-weight) and the radioactivity was measured using a γ-counter (Perkin Elmer Inc., Waltham, MA, USA) (n=5 mice/group). Tumor/non-tumor (T/ NT) ratios were calculated based on the radioscans by outlining regions of equal areas of tumor tissues and the corresponding non-tumor tissues.
SPECT imaging. Prior to being sacrificed, all the mice underwent SPECT imaging (Millennium VG; GE Healthcare, Milwaukee, WI, USA), at 2, 4 and 6 h post-injection, respectively. The mice were laid in the center of the field of view. A low-energy high-resolution parallel holes collimator was used. SPECT images were obtained with a zoom factor of 3.0 for 5 min, and were digitally stored in a 128x128 matrix and analyzed using a GE Integra workstation (GE Healthcare).
Immunohistochemistry (IHC)
. IHC was performed using a standard streptavidin-biotin-peroxidase complex method. In brief, non-specific binding was blocked with 10% normal rabbit serum for 20 min. Tumor sections were deparaffinized and rehydrated. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide for 20 min. For antigen retrieval, the sections were microwave-treated in 10 mM citrate buffer (pH 6.0) for 10 min. The sections were incubated with rabbit uPAR polyclonal antibody (1:500 dilution; Santa Cruz Biotechnology Inc., Dallas, TX, USA) overnight, then incubated with a biotinylated goat anti-rabbit immunoglobulin G antibody (1:2,000 dilution; Sigma-Aldrich, St. Louis, MO, USA) for 30 min and subsequently reacted with a streptavidin-peroxidase conjugate and 3-3'-diaminobenzidine (Sigma-Aldrich). The sections were counter-stained using Meyer's haematoxylin. Negative controls were performed by replacing the primary antibody with rabbit serum. The sections were observed under a light microscope and five fields (x400 magnification) of each section were randomly selected for analysis. The staining density was calculated based on absorbance using the Image-pro Plus 6.0 image analysis system (Media Cybernetics Inc., Rockville, MD, USA).
Statistical analysis. Statistical analysis was performed with SPSS software (version 10.0; SPSS Inc., Chicago, IL, USA). Data are presented as the mean ± standard error of the mean and were -(~10 mCi) in 80 µl S n CL 2 •H 2 O (1 mg/ml) were diluted in 160 µl Hynic-PEG-AE105 (1 mg/ml), followed by incubation at room temperature for 10 min. The radiochemical purity of Tc-Hynic-PEG-AE105mut was 97.72±1.73 and 96.70±1.32%, respectively, following Sep-Pak purification (Fig. 1) . No significant degradation of any 99m Tc-labeled peptides was observed in physiological saline following incubation for 8 h (Table I) .
Biodistribution and specificity of
99m Tc-Hynic-PEG-AE105. Next, the study investigated the in vivo pharmacokinetics of Tc-Hynic-PEG-AE105. Tc-Hynic-PEG-AE105mut. Tc, technetium-99m; ID, injected dose.
Radioactivity (%ID/g) -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
99m Tc-Hynic-PEG-AE105 and 99m Tc-Hynic-PEG-AE105 in pancreatic cancer BxPC-3 cell-bearing animals. A fast clearance rate of radiolabeled peptides from the blood and all organs investigated following resection was found (Tables II and III) .
The two radiolabeled peptides were distributed to the various organs of the body and cleared rapidly from the blood, primarily via the hepatic-intestinal route and kidneys. The tumor uptake of 99m Tc-Hynic-PEG-AE105 was significantly higher than the normal pancreatic tissue uptake at 4 h and 6 h post-injection (P<0.01), whereas the uptake in the blood was 2.87±0.13 (4 h)/2.73±0.35 (6 h), and the uptake in the muscle was 0.53±0.21 (4 h)/0.49±0.08 (4 h), thus generating a tumor-to-blood and tumor-to-muscle ratio of 1.09±0.12 (4 h)/1.11±0.20 (6 h) and 6.29±1.59 (4 h)/6.26±1.20 (6 h), respectively. The tumor uptake of the control peptide, Tc-Hynic-PEG-AE105mut, at 4 or 6 h was significantly reduced to 1.65±0.53 (4 h) and 1.41±0.38 (6 h) (P<0.01), respectively, indicating the specificity of Tc-Hynic-PEG-AE105mut, the tumor was not clear at 2, 4 and 6 h post-injection. Using quantitative region of interest analysis, a significantly higher radioactive uptake ratio (T/NT) was found for 99m Tc-Hynic-PEG-AE105 than for control peptide 99m Tc-Hynic-PEG-AE105mut at 4 h (3.37±0.11 vs. 1.36±0.18; P<0.001) and 6 h (3.64±0.25 vs. 1.28±0.20; P<0.001).
uPAR expression is correlated with the tumor uptake of 99m Tc-Hynic-PEG-AE105. IHC showed that uPAR was mainly stained in the cytoplasm and on the membrane surface of the BxPC-3 cells (Fig. 3) . Semi-quantification of uPAR staining showed that uPAR expression was not significantly different between the experimental and control groups (0.481±0.024 vs. 0.574±0.021; P= 0.173). By association analysis, a significant correlation was found between the tumor uptake of 99m Tc-Hynic-PEG-AE105 and uPAR expression at 4 to 6 h post-injection (r= 0.791, P= 0.006; Fig. 4) .
Discussion
In the present study, 99m Tc-labeled Hynic-PEG-AE105 was introduced as a SPECT tracer for imaging of uPAR expression for the first time.
99m Tc-Hynic-PEG-AE105 exhibited high affinity and specificity to uPAR in vivo, and uPAR expression was significantly correlated with the uptake of 99m Tc-Hynic-PEG-AE105 in the pancreatic cancer xenograft mouse model.
Despite its relatively low incidence, pancreatic cancer ranks fourth in the number of cancer mortalities each year (14) . Overall, <5% of individuals will survive 5 years beyond their diagnosis (15) . Therefore, novel and improved therapy options are required. Recent studies demonstrated that RNAi-mediated uPAR-knockdown was able to retard the invasive ability and angiogenic potential of cancer cells in vitro and in vivo (5, 8, 9) . These results suggest that the targeting of uPAR has significant therapeutic potential for the treatment of pancreatic cancer. For the potential clinical application of anticancer therapy based on the uPA/uPAR system, we sought to develop a non-invasive imaging method for the detection of pancreatic cancer based on uPAR expression.
Previous studies investigated the use of a high-affinity 9-mer peptide antagonist of the uPA-uPAR (AE105) for positron emission tomography (PET) imaging of uPAR expression, and showed that copper-64 ( 64 Cu)-labeled DOTA-AE105 exhibited specific and high-affinity binding to uPAR in vitro and in vivo (16) (17) (18) . However, the clinical application of this protocol is restricted due to the limited availability of 64 Cu and the high cost of PET imaging. Tc is a nuclear isomer of 99 Tc that is detectable within the body using medical equipment such as γ-ray cameras, which emit readily detectable CXL keV γ rays (the same wavelength as emitted by conventional X-ray equipment), and the half-life for γ emission is only 6 h (19). Safe and fast scanning procedures are a result of the relatively short physical half-life of 99 Tc and its biological half-life of 1 day in terms of human activity and metabolism (20) . Therefore, Tc-labeled peptides have been used for in vivo targeting of tumors, including pancreatic cancer (21) (22) (23) .
In the present study, 99m
Tc-labeled peptide was employed for SPECT imaging of uPAR in pancreatic cancer. First, the conditions for the 99m Tc labeling of Hynic-PEG-AE105 and Hynic-PEG-AE105 were optimized. It was found that under the conditions optimized, the radiochemical purity of 99m Tc-Hynic-PEG-AE105 was 97.72±1.73% following Sep-Pak purification. Similarly, the radiochemical purity of 99m Tc-Hynic-PEG-AE105mut was 96.70±1.32%. uPAR is widely expressed in pancreatic cancer cells such as Panc-1, MIA PaCa-2 and BxPC-3 (24) . Preliminary experiments in the present study showed that among these cell lines, the expression level of uPAR is the highest in the BxPC-3 cell line (data not shown), thus BxPC-3 cells were chosen for further analysis. To analyze the biodistribution and specificity of 99m Tc-Hynic-PEG-AE105 in vivo, a nude mouse xenografted with BxPC-3 cells was used as the animal model. It was found that the distribution of radioactivity in the tumor tissue was significantly higher than that in the normal tissue. Taken together, these data demonstrate the specificity of Tc-Hynic-PEG-AE105, and the uptake kept increasing and reached a plateau at 6 h post-injection. In addition, a significant correlation was found between the tumor uptake of 99m Tc-Hynic-PEG-AE105 and uPAR expression in the xenografted tumors, thus providing a strong argument for the specificity of Tc-Hynic-PEG-AE105. However, the blood clearance rate of 99m Tc-AE105 is not fast enough, leading to continued retention of the tracer in the blood, liver and kidneys, and interference in detecting the tumor lesion. Therefore, further studies are required to speed up the rate of the blood clearance of 99m Tc-AE105 and improve the imaging of the target/background ratio.
In summary, the present study reported the radiosynthesis of Tc-Hynic-PEG-AE105 in the xenografted tumor tissue was correlated with the level of uPAR expression in pancreatic cancer.
99m Tc-Hynic-PEG-AE105 is a promising agent for the non-invasive determination of uPAR expression in pancreatic cancer.
